Tim Shaw 🇺🇸..🇹🇼..🇺🇸
@gatechatl
Followers
282
Following
2K
Media
14
Statuses
648
Assistant Member/Professor, Bioinformatian & Cancer Researcher @ Moffitt. Interest in Immuno-oncology, ER stress, and alternative splicing. he/his
Tampa, FL
Joined May 2012
SmartImpute is now online with Cell Reports Methods
cell.com
Yao et al. propose SmartImpute, a target imputation framework for scRNA-seq data. They demonstrate that the integration of marker-gene-focused imputation with multi-task GAIN enables efficient and...
0
2
9
RSG SE-USA presents America’s 3rd #ComputationalBiology Symposium taking place December 11–13, 2025 at the University of Florida in St. Petersburg. This is a great chance for students to connect and plan for the future of the field!
1
1
1
If you’d like to present at the symposium, submissions are being accepted until Friday, August 15. Contact and submission details are in the flyers!
0
1
1
Researchers have been sneaking secret messages into their papers in an effort to trick AI tools into giving them a positive peer-review report Read the full story: https://t.co/1kOYRLf72i
27
199
635
In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by @US_FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,
44
434
2K
Congratulations to Michael J. Schell, Ph.D., FASA. Well deserved! 🎉🎉🎉 #Moffitt #ASA #Biostatistics #CancerResearch
0
2
11
Using ROICellTrack on urothelial carcinoma, we identified distinct cancer-immune cell mixtures linked to transcriptomic & morphological signatures. Check out our recent paper with @song_xiaofei and @UrogerliMD. https://t.co/De0uTYDUF4
#SpatialTranscriptomics
academic.oup.com
AbstractMotivation. Spatial transcriptomic (ST) technologies, such as GeoMx Digital Spatial Profiler, are increasingly utilized to investigate the role of
0
2
9
Thanks to the @KayYowFund we will be able to begin some exciting research challenging current treatment paradigms in ovarian cancer that will hopefully improve outcomes. Thank you so much for your generous support!
🏀 Big assist from the @KayYowFund! Moffitt has received a $250K grant to expand cancer research, prevention & outreach—breaking down barriers to care in underserved communities. This generous gift will bring life-saving screenings and services directly to those who need them
0
1
4
#MCBIOS2025 day 2 !! in beautiful Salt lake city @UUtah , theme - harnessing #artificialintelligence to transform #humanhealth. Dr. Tim Shaw @gatechatl and I will be co-chairing a session on #AI for #ImmunoOncology, featuring Dr. Linghua Wang @IamLinghua on her brand new
0
4
4
Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
biorxiv.org
Persisters are a sub-population of tumor cells that survive anti-cancer therapy facilitating recurrence, and have been identified following drug- and immune-therapy but are generally considered as...
0
3
16
New #JITC article: Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients https://t.co/hBM7wPADVE
@gatechatl @MoffittNews
0
7
19
Off-the-shelf CAR-T is here! Our phase 1 trial in @JCO_ASCO shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS https://t.co/JIbNWdWAeN
5
56
192
One billion cells. 🚨 One incredible dataset. Together with @10xGenomics + @UltimaGenomics, we’re working to deliver landmark data to train AI models, advancing research in gene function, cellular behavior + understanding of health & disease https://t.co/TH9zDxEk1C
2
14
42
#ScienceSaturday ➡️ Immunotherapies targeting neoantigens can be effective in mediating long-term durable responses in advanced cancer patients. However, identifying these neoantigens from metastatic tumors can be logistically challenging. 🧬 In this study, investigators
3
41
125
Great opportunity for undergrads!
Want to kickstart your career in #CancerResearch? SPARK, Moffitt Cancer Center's donor-funded summer internship, offers undergraduates hands-on experience in advancing cancer research. Learn more and apply now: https://t.co/lSK1fte7zB
1
6
14
The data science revolution is getting closer. TabPFN v2 is published in Nature: https://t.co/Ybb15pnZ5P On tabular classification with up to 10k data points & 500 features, in 2.8s TabPFN on average outperforms all other methods, even when tuning them for up to 4 hours🧵1/19
36
252
1K
One of the hardest things I do in #oncology clinic is translate results from a clinical trial to the #patient in front of me. In @NatureMedicine, we introduce TrialTranslator, a #machinelearning framework for individualized #cancer trial emulation. https://t.co/25zjFPFD8y
400
142
510
Moffitt recently made headlines by treating the world’s first patient with TCR therapy for synovial sarcoma following FDA approval. But how does TCR therapy differ from CAR T-cell therapy? Moffitt's Jose Alejandro Guevara, MD, PhD explains the distinctions between these
1
7
23
Huge thanks to Dr Vasiliki Leventaki's leadership and the team: Stanley Pounds, Alyssa Obermayer, Jinghui Zhang, @CMullighan, Megan Lim, and @wufgang. As well as support from @StJudeResearch, @MoffittNews, and @LiveLikeBella to help push this study to the finish line. 8/8
0
0
0
While ALK-fusion is the primary driver of these ALCLs, there are two types of secondary drivers underlying ALCL malignancies. Genetic events drive one type, and inflammation drives the second type. 7/8
1
0
0